natgillin/translations-raw huggingface dataset:
Hizentra is used in patients whose blood does not contain enough antibodies (proteins that help the body to fight infections and other diseases), also known as immunoglobulins. 
Zdravilo Hizentra se uporablja pri bolnikih, katerih kri ne vsebuje dovolj protiteles (beljakovin, ki pomagajo telesu v boju proti okužbam in drugim boleznim), znanih tudi kot imunoglobulini.
What benefits of Hizentra have been shown in studies? 
Kakšne koristi zdravila Hizentra so se pokazale v študijah?
Side effects reported with Hizentra are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Hizentra, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Hizentra have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Hizentra upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Why is Hizentra authorised in the EU? 
Zakaj je bilo zdravilo Hizentra odobreno v EU?
• primary immunodeficiency syndromes (PID, when people are born with an inability to produce enough antibodies); 
• sindromov primarne imunske pomanjkljivosti (pri ljudeh, ki se rodijo z nezmožnostjo proizvajanja zadostnega števila protiteles);
The patients received Hizentra for 28 weeks and the lowest IgG levels during treatment with Hizentra (average level of 8.1 g per litre) were comparable to those seen during previous immunoglobulin treatment. 
Bolniki so zdravilo Hizentra prejemali 28 tednov, najnižje ravni imunoglobulina IgG pri zdravljenju z njim (povprečna raven 8,1 g na liter) pa so bile primerljive z ravnjo, opaženo med predhodnim zdravljenjem z imunoglobulinom.
An overview of Hizentra and why it is authorised in the EU 
Pregled zdravila Hizentra in zakaj je odobreno v EU
The dose and how often Hizentra infusion is given depend on the disease being treated. 
Odmerek in pogostost infuzije sta odvisna od zdravljene bolezni.
Hizentra can only be obtained with a prescription and treatment should be started by a doctor or nurse who is experienced in the treatment of patients with weakened immune systems or CIDP. 
Predpisovanje in izdaja zdravila Hizentra je le na recept, zdravljenje z njim pa mora uvesti zdravnik ali medicinska sestra, ki ima izkušnje z zdravljenjem bolnikov z oslabljenim imunskim sistemom ali CIDP.
For more information about using Hizentra, see the package leaflet or contact a doctor or pharmacist. 
Za več informacij glede uporabe zdravila Hizentra glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
What is Hizentra and what is it used for? 
Kaj je zdravilo Hizentra in za kaj se uporablja?
What are the risks associated with Hizentra? 
Kakšna tveganja so povezana z zdravilom Hizentra?
It is given by subcutaneous infusion (very slow injection under the skin) through a device that controls the speed of infusion. 
Daje se kot infuzija v podkožje (zelo počasno injiciranje v podkožje) s pripomočkom, ki uravnava hitrost infundiranja.
• low levels of antibodies in the blood in patients with chronic lymphocytic leukaemia (a cancer of a type of white blood cell) or myeloma (a cancer of another type of white blood cell) and who have frequent infections; 
• nizke ravni protiteles v krvi bolnikov s kronično limfocitno levkemijo (rakom vrste belih krvnih celic) ali mielomom (rakom druge vrste belih krvnih celic) in pogosto ponavljajočimi se okužbami;
As human normal immunoglobulin has been used to treat these diseases for many years, in accordance with current guidelines, two small studies were needed to establish the effectiveness and safety of Hizentra in patients. 
Ker se humani polispecifični imunoglobulin že dalj časa uporablja za zdravljenje teh bolezni, sta za potrditev učinkovitosti in varnosti zdravila Hizentra pri bolnikih v skladu z veljavnimi smernicami zadostovali le dve manjši študiji.
Patients received Hizentra or placebo (a dummy treatment) for 13 weeks and the study measured the proportion of patients in whom the disease came back within 13 weeks. 
Bolniki so prejemali zdravilo Hizentra ali placebo (zdravilo brez učinkovine) 13 tednov, študija pa je merila delež bolnikov, pri katerih se je bolezen ponovila v 13 tednih.
Patients (or their carers) may inject Hizentra at home once they have been trained. 
Bolniki ali njihovi skrbniki lahko po ustreznem usposabljanju zdravilo Hizentra injicirajo sami doma.
For patients on placebo, the disease came back in about 63% of patients, for patients on Hizentra, the disease came back in 33 and 39% of patients; depending on the dose used. 
Bolezen se je ponovila pri približno 63 % bolnikov, zdravljenih s placebom, in pri 33 oziroma 39 % bolnikov, zdravljenih z zdravilom Hizentra, odvisno od uporabljenega odmerka.
Hizentra was shown to prevent serious bacterial infections in PID patients and reduce the chance of CIDP coming back. 
Dokazano je, da zdravilo Hizentra preprečuje resne bakterijske okužbe pri bolnikih s primarno imunsko pomanjkljivostjo in zmanjšuje možnost za ponovitev CIDP.
In the second study Hizentra was studied in 172 patients with CIDP who had previously received human immunoglobulin treatment by injection into a vein. 
V drugi študiji so zdravilo Hizentra proučevali pri 172 bolnikih s CIDP, ki so bili predhodno zdravljeni s humanim imunoglobulinom z injiciranjem v veno.
Hizentra must not be used in patients with hyperprolinaemia (a genetic disorder causing hgh levels of the amino acid proline in the blood). 
Zdravilo Hizentra se ne sme uporabljati pri bolnikih s hiperprolinemijo (genetsko motnjo, ki povzroča visoke ravni aminokisline prolin v krvi).
For the full list of side effects and restrictions with Hizentra, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Hizentra glejte navodilo za uporabo.
It is given in the abdomen (belly), thigh, upper arm or hip. 
Daje se v trebuh, stegno, nadlaket ali kolk.
The active substance in Hizentra, human normal immunoglobulin, is a highly purified protein extracted from donated human blood. 
Učinkovina v zdravilu Hizentra, humani polispecifični imunoglobulin, je temeljito prečiščena beljakovina, pridobljena iz darovane človeške krvi.
In the first study, Hizentra was investigated in 51 PID patients who had already received human immunoglobulin into a vein for at least six months. 
V prvi študiji so zdravilo Hizentra proučevali pri 51 bolnikih s primarno imunsko pomanjkljivostjo, ki so humani imunoglobulin prejemali v veno že vsaj šest mesecev.
Hizentra is available as a solution for injection. 
Na voljo je v obliki raztopine za injiciranje.
In this rare disease, the immune system (the body's defence system) works abnormally and destroys the protective covering over the nerves. 
(obrambni sistem telesa) deluje nenormalno in uniči zaščitno ovojnico živcev.
How is Hizentra used? 
Kako se zdravilo Hizentra uporablja?
How does Hizentra work? 
Kako zdravilo Hizentra deluje?
Hizentra works by restoring abnormally low IgG levels to their normal range in the patient's blood. 
Zdravilo Hizentra deluje tako, da nenormalno nizko koncentracijo imunoglobulina v bolnikovi krvi povrne v območje njene normalne vrednosti.
Hizentra contains the active substance human normal immunoglobulin. 
Zdravilo Hizentra vsebuje učinkovino humani polispecifični imunoglobulin.
• low levels of antibodies in the blood in patients before or after allogeneic haematopoietic stem cell transplantation (a procedure where the patient's bone marrow is cleared of cells and replaced by stem cells from a donor); 
(postopkom, pri katerem se iz bolnikovega kostnega mozga odstranijo celice in nadomestijo z matičnimi celicami darovalca) ali po njej;
10 vials + 10 vials 
10 vial + 10 vial
1 vial + 1 pre-filled syringe + 1 needle 
1 viala + 1 napolnjena injekcijska brizga + 1 igla
10 vials + 10 prefilled syringes with attached needle 
10 napolnjenih injekcijskih brizg z nameščenimi iglami
1 vial + 1 pre-filled syringe + 2 needles 
1 napolnjena injekcijska brizga + 2 igli
1 vial + 1 pre-filled syringe without needle 
1 napolnjena injekcijska brizga brez igle
1 vial + 1 pre-filled syringe with attached needle 
1 napolnjena injekcijska brizga z nameščeno iglo
They must not give you any food or drink. 
Ne smejo vam dajati hrane ali pijače.
Bear in mind that you could endanger yourself or others. 
Vedite, da s tem lahko ogrozite sebe ali druge.
OTHER SPECIAL WARNINGS, IF NECESSARY 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
The exact mechanism of this interaction is not clear. 
Natančen mehanizem te interakcije ni pojasnjen.
Date of first authorisation: 14/10/2009 Date of latest renewal: 22 August 2014 
Datum prve odobritve: 14. oktober 2009 Datum zadnjega podaljšanja: 22 avgust 2014
• if you are under 18 or over 75 years of age. 
- če ste mlajši od 18 ali starejši od 75 let.
It could choke you. 
Lahko vas zaduši.
If you miss a dose, take the next dose as usual. 
Če ste pozabili vzeti odmerek, naslednji odmerek vzemite kot ponavadi.
Very rare 
zelo redki
The safety and efficacy of repaglinide in children below 18 years have not been established. 
Varnost in učinkovitost repaglinida pri otrocih, mlajših od 18 let, še nista bili dokazani.
Repaglinide was detected in the milk of animals. 
Repaglinid so zasledili v mleku živali.
• if you are about to have major surgery or you have recently suffered a severe illness or infection. 
- če imate predvideno večjo operacijo ali ste pred kratkim preboleli hudo bolezen ali okužbo.
If this happens, medical assistance is needed immediately. 
V takšnih primerih morate nemudoma poiskati zdravniško pomoč.
Combination with metformin 
Kombinacija z metforminom
Summary of the safety profile 
Povzetek profila varnosti
No safety concerns were raised. 
Težav z varnostjo niso ugotovili.
- Diabetic ketoacidosis, with or without coma. 
- Diabetična ketoacidoza s komo ali brez nje.
Data from animal studies investigating effects on embryofetal and offspring development as well as excretion in milk is described in section 5.3. 
Podatki iz študij na živalih, ki so preučevale vplive na embrio-fetalni razvoj in razvoj potomstva ter izločanje v mleko, so opisani v poglavju 5.3.
Your doctor will advise you. 
O tem vam bo svetoval zdravnik.
V. Holjevca 20/E 10450 Jastrebarsko Croatia 
V. Holjevca 20/E 10450 Jastrebarsko Hrvaška
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
If any change of your treatment is necessary contact your doctor first. 
Če je potrebna kakršnakoli sprememba zdravljenja, se najprej posvetujte s svojim zdravnikom.
The dosage should be determined by the physician, according to the patient's requirements. 
Odmerek mora določiti zdravnik glede na bolnikove potrebe.
Debilitated or malnourished patients 
Oslabeli in podhranjeni bolniki
Talk to your doctor. 
Posvetujte se s svojim zdravnikom.
Repaglinide is eliminated rapidly within 4 - 6 hours from the blood. 
Repaglinid se iz krvi hitro izloči, v 4 do 6 urah.
Enyglid has no or negligible influence on the ability to drive and use machines but may cause hypoglycaemia. 
Zdravilo Enyglid nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji, vendar pa lahko povzroči hipoglikemijo.
- Diabetes mellitus type 1, C-peptide negative. 
- Sladkorna bolezen tipa 1 (na C-peptid negativna).
The total maximum daily dose should not exceed 16 mg. 
Skupni največji dnevni odmerek ne sme preseči 16 mg.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom, preden vzamete to zdravilo.
Special patient groups 
Posebne skupine bolnikov
Do not use this medicine after the expiry date which is stated on the blister and outer carton. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in škatli.
The plasma elimination half-life is approximately one hour. 
Plazemski razpolovni čas izločanja znaša približno 1 uro.
Repaglinide has been given with weekly escalating doses from 4 - 20 mg four times daily in a 6 week period. 
Repaglinid so uporabljali v tedensko naraščajočih odmerkih od 4 do 20 mg štirikrat na dan 6 tednov.
At such times, it may be necessary to discontinue repaglinide and treat with insulin on a temporary basis. 
V takšnih primerih utegne biti potrebna prekinitev uporabe repaglinida in začasno zdravljenje z insulinom.
In addition to the usual self-monitoring by the patient of blood and/or urinary glucose, the patient's blood glucose must be monitored periodically by the physician to determine the minimum effective dose for the patient. 
Poleg običajne samokontrole glukoze v krvi in/ali urinu, ki jo izvaja bolnik, mora bolnikovo glukozo v krvi redno nadzirati tudi zdravnik, da določi za bolnika najmanjši učinkoviti odmerek.
Talk to your doctor if any of the above applies to you. 
Obvestite zdravnika, če se karkoli od naštetega nanaša na vas.
This may be due to progression of the severity of the diabetes or to diminished responsiveness to the medicinal product. 
To je lahko posledica napredovanja sladkorne bolezni ali zmanjšanja odzivnosti na zdravilo.
The occurrence of such reactions depends on individual factors, such as dietary habits, dosage, exercise and stress. 
Pojavnost takšnih reakcij je odvisna od individualnih dejavnikov, kot so prehranske navade, uporabljen odmerek, telesna dejavnost in stres.
Changes in blood glucose levels have been known to result in transient visual disturbances, especially at the commencement of treatment. 
Znano je, da spremembe v koncentraciji glukoze v krvi povzročijo prehodne motnje vida, še posebej na začetku zdravljenja.
- Hypersensitivity to repaglinide or to any of the excipients listed in section 6.1. 
- Preobčutljivost na repaglinid ali katero koli pomožno snov, navedeno v poglavju 6.1.
Repaglinide is a short-acting oral secretagogue. 
Repaglinid je nov kratkotrajno delujoči peroralni sekretagog.
Watch for signs of a hypo. 
Bodite pozorni na znake hipoglikemije.
TAD Pharma GmbH Heinz-Lohmann-Straße 5 27472 Cuxhaven Germany 
TAD Pharma GmbH Heinz-Lohmann-Straße 5 27472 Cuxhaven Nemčija
In this case, the dosage of metformin should be maintained and repaglinide administered concomitantly. 
V tem primeru je treba odmerjanje metformina ohraniti in sočasno uporabljati še repaglinid.
This resulted in a blood glucose-lowering effect throughout the meal period. 
To je povzročilo znižanje glukoze v krvi v celotnem obdobju obroka.
When repaglinide is used together with other medicinal products that are mainly secreted by the bile, like repaglinide, any potential interaction should be considered. 
Če se repaglinid uporablja skupaj z drugimi zdravili, ki se izločajo predvsem z žolčem, tako kot repaglinid, je treba upoštevati morebitne interakcije.
• if you have liver problems. 
- če imate težave z ledvicami.
Clinical study results have shown that repaglinide is optimally dosed in relation to main meals (preprandial dosing). 
Izsledki kliničnih študij kažejo, da je repaglinid optimalno uporabiti ob glavnih obrokih (predprandialno odmerjanje).
Generalised hypersensitivity reactions (e.g. anaphylactic reaction), or immunological reactions such as vasculitis. 
Generalizirane preobčutljivostne reakcije (npr. anafilaktična reakcija) ali imunološke reakcije, npr. vaskulitis.
Swallow the tablets with a glass of water immediately before or up to 30 minutes before each main meal. 
Tablete vzemite s kozarcem vode tik pred ali do 30 minut pred vsakim glavnim obrokom.
The elevated insulin levels did not persist beyond the time of the meal challenge. 
Zvečana koncentracija inzulina ni trajala dlje izziv z obrokom.
Repaglinide should be avoided during pregnancy. 
Med nosečnostjo se je treba uporabi repaglinida izogibati.
Allergy is very rare (may affect up to 1 in 10,000 people). 
Alergija je zelo redka (lahko se pojavi pri največ 1 od 10.000 bolnikov).
A small fraction (less than 8%) of the administered dose appears in the urine, primarily as metabolites. 
Manjši del (manj kot 8 %) uporabljenega odmerka se izloči z urinom, v glavnem v obliki presnovkov.
Elderly No clinical studies have been conducted in patients >75 years of age. 
Starostniki Klinične študije pri bolnikih, starejših od 75 let, niso bile izvedene.
Tell people you have diabetes and that if you pass out (become unconscious) due to a hypo, they must turn you on your side and get medical help straight away. 
Ljudem povejte, da ste sladkorni bolnik in naj vas v primeru, če se onesvestite (izgubite zavest), položijo na bok in nemudoma poiščejo zdravniško pomoč.
If severe hypoglycaemia is not treated, it can cause brain damage (temporary or permanent) and even death. 
- Dolgotrajna nezdravljena huda hipoglikemija lahko povzroči (prehodno ali trajno) okvaro možganov in celo smrt.
Combination treatment with metformin is associated with an increased risk of hypoglycaemia. 
Kombinirano zdravljenje z metforminom spremlja večje tveganje za pojav hipoglikemije.
Enyglid may not be suitable for you. 
Zdravljenje z zdravilom Enyglid pri vas morda ni primerno.
Periodic monitoring is necessary to detect inadequate lowering of blood glucose at the recommended maximum dose level (i.e. primary failure) and to detect loss of adequate blood-glucose lowering response after an initial period of effectiveness (i.e. secondary failure). 
Redno spremljanje je potrebno zato, da bi odkrili nezadostno znižanje glukoze v krvi ob priporočenem največjem odmerka (tj. primarna odpoved), ali nezadostno znižanje glukoze po uvodnem obdobju učinkovitosti (tj. sekundarna odpoved).
Your diabetes may get worse. 
Urejenost sladkorne bolezni se lahko poslabša.
Substances that inhibit OATP1B1 may likewise have the potential to increase plasma concentrations of repaglinide, as has been shown for ciclosporin (see below). 
Učinkovine, ki zavirajo OATP1B1, lahko morda povečajo koncentracijo repaglinida v plazmi zvišajo podobno, kot je ugotovljeno za ciklosporin (glejte v nadaljevanju).
This depolarises the β-cell and leads to an opening of the calcium channels. 
To depolarizira celico β in povzroči odprtje kalcijevih kanalov.
* see section Description of selected adverse reactions below 
* glejte poglavje Opis izbranih neželenih učinkov v nadaljevanju
This phenomenon is known as secondary failure, to distinguish it from primary failure, where the medicinal product is ineffective in an individual patient when first given. 
Pojav je poznan kot sekundarna odpoved, za razliko od primarne odpovedi, pri kateri je zdravilo neučinkovito, že ko ga bolnik vzame prvič.
One epidemiological study suggested an increased risk of acute coronary syndrome in repaglinide treated patients as compared to sulfonylurea treated patients (see sections 4.4 and 4.8). 
Ena epidemiološka študija je nakazala večje tveganje za razvoj akutnega koronarnega sindroma pri bolnikih, zdravljenih z repaglinidom, v primerjavi z bolniki, zdravljenimi z derivati sulfonilsečnine (glejte poglavji 4.4 in 4.8).
- Concomitant use of gemfibrozil (see section 4.5). 
- Sočasna uporaba gemfibrozila (glejte poglavje 4.5).
Rare (may affect up to 1 in 1,000 people): • Acute coronary syndrome (but it may not be due to the medicine). 
Redki (pojavijo se lahko pri največ 1 od 1.000 bolnikov) - akutni koronarni sindrom (ki pa ni nujno povezan z uporabo zdravila)
More severe hypoglycaemia with seizure, loss of consciousness or coma should be treated with intravenous glucose. 
Hujšo hipoglikemijo s krči, izgubo zavesti ali komo je treba zdraviti z intravensko aplikacijo glukoze.
Based on in vitro data, repaglinide appears to be a substrate for active hepatic uptake (organic anion transporting protein OATP1B1). 
Podatki pridobljeni in vitro kažejo, da je repaglinid substrat aktivnega prevzema v jetrih (transportna beljakovina organskih anionov OATP1B1).
Repaglinide should be taken before main meals (i.e. preprandially). 
Bolnik mora repaglinid vzeti pred glavnimi obroki (tj. predprandialno).
30 tablets 60 tablets 90 tablets 120 tablets 180 tablets 270 tablets 360 tablets 
30 tablet 60 tablet 90 tablet 120 tablet 180 tablet 270 tablet 360 tablet
Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal (i.e. preprandially 2, 3, or 4 meals a day). 
Odmerek se običajno vzame 15 minut pred obrokom, vendar pa lahko čas zaužitja sega od 30 minut pred obrokom do tik pred njim (tj. predprandialno, v primeru 2, 3 ali 4 obrokov na dan).
Do not take a double dose to make up for a forgotten tablet. 
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
Trials investigating the combination with other insulin secretagogues have not been performed. 
Preskušanja, ki bi proučila kombinacijo z drugimi sekretagogi inzulina, niso bila izvedena.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu/. 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/.
The maximum recommended daily dose is 16 mg. 
Največji priporočeni dnevni odmerek je 16 mg.
No interaction studies have been performed in children and adolescents. 
Študij medsebojnega delovanja z drugimi zdravili pri otrocih in mladostnikih niso izvedli.
In type 2 diabetic patients, the insulinotropic response to a meal occurred within 30 minutes after an oral dose of repaglinide. 
Pri bolnikih s sladkorno boleznijo tipa 2 se je inzulinotropni odziv na obrok pojavil v 30 minutah po peroralnem odmerku repaglinida.
Hypoglycaemic reactions are generally mild/moderate but may occasionally develop into hypoglycaemic unconsciousness or coma. 
Hipoglikemične reakcije so običajno blage/zmerne, v posameznih primerih pa lahko napredujejo do hipoglikemične nezavesti ali kome.
Boxes of 30, 60, 90, 120, 180, 270 or 360 tablets in blisters are available. 
Na voljo so škatle s 30, 60, 90, 120, 180, 270 ali 360 tabletami v pretisnih omotih.
Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals. 
Zdravljenje je treba uvesti kot dodatek k dieti in telesni dejavnosti za znižanje koncentracije glukoze v krvi ob obrokih.
Repaglinide is given preprandially and is titrated individually to optimise glycaemic control. 
Repaglinid se uporablja predprandialno in ga je treba za optimiranje urejenosti glikemije individualno prilagoditi.
Type 2 diabetes is a disease in which your pancreas does not make enough insulin to control the sugar in your blood or where your body does not respond normally to the insulin it produces. 
Sladkorna bolezen tipa 2 je bolezen, pri kateri trebušna slinavka (pankreas) ne tvori dovolj inzulina, da bi uravnal koncentracijo sladkorja v krvi ali pa se telo ne odziva normalno na inzulin, ki ga sam proizvaja.
In very rare cases, severe hepatic dysfunction has been reported. 
V zelo redkih primerih so poročali o pojavu zelo hudih motenj delovanja jeter.
Should these symptoms occur, adequate action should be taken to correct the low blood glucose (oral carbohydrates). 
Če se ti simptomi pojavijo, je treba ustrezno ukrepati, da bi odpravili nizko koncentracijo glukoze v krvi (zaužitje ogljikovih hidratov).
Combination with Neutral Protamine Hagedorn (NPH) insulin or thiazolidinediones 
Kombinacija z inzulinom NPH (Neutral Protamine Hagedorn) ali s tiazolidindioni
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Croatia 
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenija TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Nemčija KRKA - FARMA d.o.o., V. Holjevca 20/E, 10450 Jastrebarsko, Hrvaška